Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement


Correspondence: Parameswaran N. Hari, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Suite C5500, Milwaukee 53226, WI, USA.



Pre-existing central nervous system (CNS) involvement may influence referral for autologous haematopoietic cell transplantation (AHCT) for patients with non-Hodgkin lymphoma (NHL). The outcomes of 151 adult patients with NHL with prior secondary CNS involvement (CNS+) receiving an AHCT were compared to 4688 patients without prior CNS lymphoma (CNS). There were significant baseline differences between the cohorts. CNS+ patients were more likely to be younger, have lower performance scores, higher age-adjusted international prognostic index scores, more advanced disease stage at diagnosis, more aggressive histology, more sites of extranodal disease, and a shorter interval between diagnosis and AHCT. However, no statistically significant differences were identified between the two groups by analysis of progression-free survival (PFS) and overall survival (OS) at 5 years. A matched pair comparison of the CNS+ group with a subset of CNS patients matched on propensity score also showed no differences in outcomes. Patients with active CNS lymphoma at the time of AHCT (n = 55) had a higher relapse rate and diminished PFS and OS compared with patients whose CNS lymphoma was in remission (n = 96) at the time of AHCT. CNS+ patients can achieve excellent long-term outcomes with AHCT. Active CNS lymphoma at transplant confers a worse prognosis.

Non-Hodgkin lymphomas (NHL) have the potential for extranodal involvement with predilection for bone marrow, central nervous system (CNS), testes, and other sites. In aggressive NHL subtypes, such as Burkitt lymphoma and lymphoblastic lymphoma, CNS involvement is reported as high as 30% whereas in diffuse large B cell lymphoma (DLBCL), CNS involvement is reported in 1–7% of patients at diagnosis or at relapse (Siegal & Goldschmidt, 2012). Low grade lymphomas also can involve the CNS, but with lower incidence. Irrespective of histological subtype, CNS involvement is therapeutically challenging and associated with worse outcomes.

Autologous haematopoietic stem cell transplantation (AHCT) is a standard of care for eligible patients with relapsed NHL. There are few series evaluating the impact of prior CNS lymphomatous involvement on the outcome of AHCT. CNS involvement by lymphoma has been associated with worse prognosis and is a therapeutic challenge. A registry analysis by the European Group for Blood and Marrow Transplant (EBMT) in 1994 of 62 patients reported that CNS remission at AHCT predicted better outcomes. Long-term progression-free survival (PFS) was 9% for those with active CNS disease versus 42% for those in CNS remission at transplant (Williams et al, 1994). Retrospective, single centre studies (van Besien et al, 1996, 1998; Alvarnas et al, 2000; Kasamon et al, 2005) mostly confirm these results. However, many of the studies were performed in the era before rituximab and prior to the application of aggressive treatment regimens for patients with higher risk disease. However, even with more modern regimens incorporating rituximab and intrathecal and/or systemic methotrexate, the rate of CNS relapse post primary therapy for large cell lymphoma has only been slightly reduced (Boehme et al, 2009; Villa et al, 2010). The current study was designed to determine the outcomes of AHCT in patients with NHL and prior CNS involvement (excluding primary CNS lymphoma).

Patients and methods

Data sources

The Center for International Blood and Marrow Transplant Research (CIBMTR) is a combined research programme of the Medical College of Wisconsin and the National Marrow Donor Programme (NMDP). CIBMTR comprises a voluntary network of more than 450 transplantation centres worldwide that contribute detailed data on consecutive allogeneic and autologous haematopoietic cell transplants to a centralized Statistical Center. Observational studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. Protected Health Information used in the performance of such research is collected and maintained in CIBMTR's capacity as a Public Health Authority under the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. Additional details regarding the data source are described elsewhere (Horowitz, 2008).


Outcomes of adult patients (>18 years) with systemic NHL with (151) or without (4688) CNS involvement, who underwent AHCT between 1990 and 2005 are reported. CNS involvement (CNS+) was defined and classified as NHL involvement of brain or spinal cord parenchyma or leptomeningeal involvement or both at any time prior to AHCT. Patients with primary CNS lymphoma were excluded.

End points

Primary outcomes included non-relapse mortality (NRM), progression/relapse, PFS, and overall survival (OS). NRM was defined as death from any cause in the first 28 d after AHCT or death without evidence of lymphoma progression/relapse. Progression was defined as an increase of ≥25% in the sites of lymphoma or development of new sites of lymphoma. Relapse was defined as recurrence of lymphoma after a complete response (CR). For PFS, patients were considered treatment failures at the time of relapse/progression or death from any cause. Patients alive without evidence of NHL relapse or progression were censored at last follow up and the PFS event was summarized by a survival curve. The OS interval variable was defined as the time from date of transplant to date of death or last contact and summarized by a survival curve.

Statistical analysis

Patient-, disease- and transplant-related variables for the two study groups were compared using the chi-square statistic for categorical and the Kruskal–Wallis test for continuous variables. Univariate probabilities of PFS and OS were calculated using the Kaplan–Meier estimator. Probabilities of NRM and relapse/progression were calculated using cumulative incidence curves to accommodate competing risks.

Matched pair analysis

A matched pair comparison was performed on a subset of 135 CNS+ patients with follicular lymphoma, DLBCL, Burkitt lymphoma and lymphoblastic histology and a matched CNS control group. Propensity score method was used to match for pretransplant disease characteristics between the groups by fitting a logistic regression model (D'Agostino, 1998). Matching on propensity scores generated from the model addressed the imbalance between the 2 groups across major risk factors and allowed us to exclude control subjects in the non-overlapping ranges of the propensity score. This resulted in similar cohorts of CNS+ and CNS patients allowing comparison of AHCT outcomes between these groups (Table SI).

A numeric propensity score for each CNS+ transplant was calculated using the following significant variables from the model: age at AHCT, histology (follicular versus DLCL versus lymphoblastic), second line age-adjusted International Prognostic Index (IPI) score, disease status at transplant, year of AHCT and time from diagnosis to transplant. For the CNS+ group, the median propensity score was 0·0417. For the pooled CNS sample, the median propensity score was 0·0343. The aim was to identify four matches from the CNScohort for each CNS+ patient for the matched pair analysis. CNS+ transplant recipients (cases) were matched in random order to CNS transplant recipients (controls) with similar propensity scores. Any CNS (control) patient with a difference in the propensity score within one standard error from the pooled CNS+ sample was considered a potential matched control and a control patient with the smallest difference in propensity score from among all potential matched controls was selected. These steps were repeated among cases until four controls were identified for each of the cases.

For 135 CNS+ cases, 535 CNS controls were identified. Median follow-up and risk factor variables used for propensity score were confirmed to be similar between the 2 cohorts. Validation of the selected CNS control group (n = 535) was performed by confirming similar survival probability with the original CNS control group from which the cases were drawn. Baseline subject-, disease-, and transplant-related variables for the CNS+ and the CNS matched groups were compared. Multivariate analysis was performed by fitting a Cox model stratified on matched-pairs.


Patient, disease, and transplant characteristics of subjects receiving an AHCT for NHL with or without pre-existing CNS involvement are shown in Table 1. There were significant differences between these cohorts, as might be anticipated. Recipients with prior CNS lymphoma were younger, had a shorter interval between diagnosis and AHCT, lower performance scores, more advanced second line age-adjusted IPI scores at transplant, more aggressive histology, more advanced disease stage and a greater frequency of extranodal lymphoma. Univariate probabilities of outcomes of interest after AHCT between the CNS+ and CNS cohort are summarized in Table 2. NRM, PFS, relapse risk and OS did not differ between the groups early after transplantation and at one, three and 5 years. The majority of relapses in either cohort were outside of the CNS compartment. Karnofsky score post AHCT (at last reported contact) was similar between cohorts and ≥90 in two-thirds of the patients in each cohort. Finally, the CNS+ cohort was examined to discern if there was in impact on survival of pre-transplant parenchymal versus leptomeningeal involvement. No difference in OS at 100 d, 1 year, 3 years or 5 years could be determined (= 0·41; data not shown).

Table 1. Comparison of adult AHCT recipients for NHL with no CNS involvement versus. pre- existing CNS involvement
N evaln (%)N evaln (%)
Patient related
Number of patients 4688 151 
Age, median (range), years468851 (18–82)15146 (18–72)<0·001
Male sex46882835 (60)15196 (64)0·44
Karnofsky score pre-transplant4541 142 <0·001
<80 320 (7) 27 (19) 
80–90 1133 (25) 35 (25) 
90–100 3088 (68) 80 (56) 
Disease related0·005
Second line age-adjusted International Prognostic Index (IPI) at transplant3384 104 
Low 1329 (39) 36 (35)
Low-Intermediate 1407 (42) 38 (37)
High-Intermediate 580 (17) 23 (22)
High 68 (2) 7 (7)
LDH>upper limit of normal at diagnosis19221002 (52)6646 (70)0·005
Disease stage at diagnosis4688 151 <0·001
I 468 (10) 13 (9)
II 889 (19) 14 (9)
III 1115 (24) 14 (9)
IV 2216 (47) 110 (73)
Histological diagnosis4688 151 <0·001
Follicular lymphoma 1301 (28) 22 (15)
DLBCL 2413 (51) 83 (55)
Lymphoblastic/Burkitt/Burkitt-like 189 (4) 39 (26)
Mantle cell lymphoma 423 (9) 3 (2)
Other 362 (8) 4 (3)
Immunophenotype for NHL patients4688 151 0 ·16
B-cell 4464 (95) 140 (93)
T-cell 224 (5) 11 (7)
B Symptoms at diagnosis43891729 (39)14256 (39)0 ·99
Non-CNS extranodal disease 3092 (66) 130 (86)<0·001
HIV Positive 12 (<1) 2 (1)0 ·02
Number of prior lines of therapy4664 151 0 ·70
1 803 (17) 26 (17)
2–3 2935 (63) 90 (60)
≥4 918 (20) 35 (23)
Unknown 8 (<1) 0
N evaln (%)N evaln (%)
  1. AHCT, autologous haematopoietic stem cell transplantation; CNS, without prior central nervous system lymphoma; CNS+, prior central nervous system lymphoma; N eval, number evaluable; LDH, lactate dehydrogenase; DLBCL, diffuse large B cell lymphoma; NHL, non-Hodgkin lymphoma; HIV, human immunodeficiency virus; TBI, total body irradiation; BEAM, carmustine, etoposide, cytarabine, melphalan; CBV, cyclophosphamide, carmustine, etoposide; BuMEL, busulfan and melphalan; BuCy, busulfan and cyclophosphamide.

CNS irradiation as part of therapy   151   
None   104 (69) 
Cranial-spinal   4 (3) 
Brain   23 (15) 
Spine   20 (13) 
Disease status at transplant4670 151 0·84
Chemotherapy sensitive 3587 (77) 119 (79)
Chemotherapy Resistant 454 (10) 13 (9)
Unknown sensitivity PIF/Relapse 649 (13) 19 (13)
Interval from diagnosis to transplant, median (range), months468515 (1–389)15112 (3–137)0·002
Interval from most recent relapse to transplant, median (range), months31664 (<1–89)1013 (<1–71)0 ·10
Conditioning regimen4688 151 0 ·20
TBI-based 1171 (25) 35 (23)
BEAM and similar 2464 (53) 70 (46)
CBV or similar 429 (9) 20 (13)
BuMEL/BuCy 323 (7) 15 (10)
Others 301 (6) 11 (7)
Radiation in conditioning regimen46791225 (26)15143 (28)0 ·65
Rituxan in conditioning regimen468896 (2)1511 (1)0 ·23
Planned radiation therapy post-transplant4658501 (11)15021 (14)0 ·21
Planned chemo therapy post-transplant4658168 (4)15012 (8)0·005
Site of post-transplant relapse3153 90 <0·001
No relapse 2065 (65) 57 (63)
Relapsed at CNS 5 (<1) 1 (1)
Relapsed at non-CNS site 1020 (32) 25 (28)
CNS and Other sites 63 (2) 7 (8)
Karnofsky score at last contact3624 106 0 ·78
<80 431 (12) 15 (14)
80–90 751 (21) 21 (20)
90–100 2442 (67) 70 (66)
Median follow-up of survivors, months230373 (<1–200)6477 (1–174)
Table 2. Outcomes of adult AHCT recipients for NHL with no CNS involvement versus pre-existing CNS involvement
N EvalProbability (95% CI)N EvalProbability (95% CI)
  1. AHCT, autologous haematopoietic stem cell transplantation; CNS, without prior central nervous system lymphoma; CNS+, prior central nervous system lymphoma; N eval, number evaluable; 95% CI, 95% confidence interval.

Relapse4618 150 0·075
100-d351320 (18–21)10624 (18–31)
1 years240739 (37–40)6848 (40–56)
3 years148352 (51–54)4657 (49–65)
5 years98657 (55–58)3161 (53–69)
Non-relapse mortality4618 150 0·756
100-d35134 (3–4)1065 (2–9)
1 years24075 (5–6)685 (2–10)
3 years14837 (6–8)467 (3–11)
5 years9868 (8–9)319 (5–14)
Disease-free survival4618 150 0·127
100-d351377 (76–78)10671 (64–78)
1 years240756 (54–57)6847 (39–55)
3 years148341 (39–42)4636 (28–44)
5 years98635 (33–36)3130 (23–38)
Overall survival4688 151 0·079
100-d416790 (89–91)12685 (78–90)
1 years311171 (70–73)9264 (56–72)
3 years207457 (56–59)5948 (40–56)
5 years139649 (48–51)4342 (34–51)

The CNS+ cohort was further analysed and stratified by CNS remission status at the time of AHCT. Significantly inferior outcomes were observed for those with active CNS lymphoma at AHCT (see Fig 1 and Table 3). At 100 d, 1 year and 3 years post-AHCT, the cumulative incidence of relapse was 33% [95% confidence interval (CI): 21–46%], 63% (95% CI 49–75%) and 72% (95% CI 59–83%) for those with active CNS lymphoma compared with 19% (95% CI 12–27%), 39% (95% CI 30–49%) and 49% (95% CI 38–59%) in those in CNS remission at the time of AHCT. PFS at 100 d, 1 and 3 years was lower in the cohort with active CNS disease at AHCT 58% (95% CI 45–71%), 28% (95% CI 17–41%) and 19% (95% CI 10–30%), vs. 79% (95% CI 70–86%), 57% (95% CI 47–67%) and 46% (95% CI 36–56%) in those in a CNS remission. OS at 100 d, 1 year and 3 years was also inferior for those with active CNS disease at AHCT 78% (95% CI 66–88%), 49% (95% CI 35–62%), 31% (95% CI 19–44%) vs. 88% (95% CI 81–94%), 73% (95% CI 64–82%) and 58% (95% CI 47–68%), for those in CNS remission at transplant.

Table 3. Outcomes of patients with pre-existing CNS involvement, by CNS disease status at AHCT
OutcomeCNS remission at AHCTActive CNS disease at AHCTP-value
N EvalProbability (95% CI)N EvalProbability (95% CI)
  1. AHCT, autologous haematopoietic stem cell transplantation; CNS, central nervous system; N eval, number evaluable; 95% CI, 95% confidence interval.

Relapse95 55 <0·001
100-d7419 (12–27)3233 (21–46)
1 years5339 (30–49)1563 (49–75)
3 years3649 (38–59)1072 (59–83)
Non-relapse mortality95 55 0·099
100-d742 (0–6)329 (3–18)
1 years533 (1–8)159 (3–18)
3 years365 (2–11)109 (3–18)
Disease-free survival95 55 <0·001
100-d7479 (70–86)3258 (45–71)
1 years5357 (47–67)1528 (17–41)
3 years3646 (36–56)1019 (10–30)
Overall survival96 55 <0·001
100-d8388 (81–94)4378 (66–88)
1 years6673 (64–82)2649 (35–62)
3 years4558 (47–68)1431 (19–44)
Figure 1.

Cumulative incidence of relapse, progression-free survival and overall survival comparing patients with active CNS disease at time of transplantation (dashed line) with patients with CNS remission status at AHCT (solid line). REL, relapse, PFS, progression-free survival; OS, overall survival; AHCT, autologous haematopoietic stem cell transplantation; CNS, central nervous system; CI, cumulative incidence; Prob, probability.

As there were significant baseline differences between the overall CNS+ and CNS cohorts, a matched pair comparison was performed between 135 patients with follicular lymphoma, DLBCL, Burkitt lymphoma and lymphoblastic NHL with CNS disease and a subset (n = 535) of closely matched patients that lacked CNS involvement. Advanced disease stage at diagnosis, marrow involvement and extranodal disease were more likely to be associated with the CNS+ cohort. Otherwise, the matched cohorts were well balanced with respect to age, sex, performance status, lymphoma stage, chemotherapy sensitivity, time from diagnosis, rituximab exposure (see Table SI.). Multivariate analysis was performed using Cox regression models stratified on matched pairs. There was no significant differences in relapse (= 0·5572), treatment-related mortality (P = 0·8968), PFS (P = 0·6152) or OS (P = 0·2469) between these cohorts (Fig 2). The major cause of death (>75%) of patients within this analysis was relapse/progression of NHL.

Figure 2.

Comparison of patients from the CNS+ cohort (selected by disease histology) with a matched control group with no CNS involvement prior to AHCT. Cumulative incidence of relapse and non-relapse mortality, and Kaplan–Meier probabilities for PFS and OS shown. TRM, treatment-related mortality; REL, relapse, PFS, progression-free survival; OS, overall survival; AHCT, autologous haematopoietic stem cell transplantation; CNS, central nervous system; CNS+, prior central nervous system lymphoma; CI, cumulative incidence; Prob, probability.


The outcomes of patients with CNS involvement of NHL are variable. There are subsets of highly aggressive lymphoma, which commonly are associated with involvement of the CNS early in the natural history, for which therapeutic regimens have been designed to provide CNS therapy as part of upfront management. However, for the vast majority of lymphoma patients, CNS involvement occurs late and can be associated with inferior outcomes. Multiple salvage modalities have been developed, including systemic and intrathecal/intraventricular chemotherapy, radiation therapy, and recently, intrathecal/intraventricular administration of therapeutic antibodies (Villela et al, 2008; Jaime-Perez et al, 2009). However, decision-making regarding therapy is influenced by the extent of CNS involvement - leptomeningeal or parenchymal relapse or a combination of both and also, on our diagnostic ability to determine persistent disease, recognizing the failure of radiological imaging to truly delineate remission status from ongoing disease, and as well the evolution of imaging technology over the past two decades.

AHCT is another therapeutic modality available to lymphoma patients with CNS involvement. Both autologous and allogeneic HCT have been performed, although in the latter circumstance, only small anecdotal reports exist. In contrast, prior experience with AHCT has demonstrated that this modality can be safe and efficacious.

From a cohort of 605 newly diagnosed patients with intermediate grade and immunoblastic lymphoma, the MD Anderson group identified 24 patients with CNS disease at relapse (van Besien et al, 1998). Those with CNS recurrence had worse prognosis and only four of the 20 patients with prior CNS involvement remained free of disease. Another retrospective evaluation of patients receiving high dose therapy with pre-existing CNS involvement for NHL at Stanford University Medical Center indicated that if disease control was achieved, better outcomes were obtained with an actuarial 5-year PFS and OS of 46% and 41%, respectively, in the 15 AHCT recipients with CNS involvement (out of 481 NHL patients) (Alvarnas et al, 2000). This study confirmed that AHCT could provide extended PFS in patients with secondary CNS lymphoma and even possibly in patients with recurrent primary CNS lymphoma. Similar observations were reported from the Johns Hopkins Medical Center, where 37 lymphoma patients who had CNS involvement were treated into remission by the time of either autologous (59%) or allogeneic (41%) HCT (Kasamon et al, 2005). Age ≥18 years, resistant systemic disease, busulfan and cyclophosphamide conditioning and lack of intrathecal consolidation were associated with inferior survival, as was CNS involvement at the time of relapse as opposed to time of diagnosis. Most notably, 5-year survival rates (actuarial OS = 39%) were not dissimilar to those seen in other high risk lymphoma patients without CNS disease undergoing HCT, suggesting that pre-existing CNS disease was not a contraindication to proceeding with transplantation efforts. Cote et al (2012) presented data on 16 patients with secondary CNS lymphoma of various histologies, demonstrating the efficacy of AHCT. The majority (13/16) of patients underwent AHCT at first response with 11 patients in CR, 4 in PR and 1 with stable/progressive disease at time of transplant (Cote et al, 2012). Excellent outcomes were reported with 93% OS and 90% PFS at 1 year. In a prospective phase II study, Korfel et al (2013) treated 24 patients with relapsed secondary CNS lymphoma with 3 cycles of induction therapy followed by AHCT. Survival at 2 years was 68% for AHCT recipients but 6 out of the 30 enrolled patients could not proceed to transplant.

Despite these promising published results there has been a reluctance to refer patients for transplantation, given the perceived poor outcomes for this lymphoma patient subpopulation. We recognize that many patients are never referred to transplant centres and this current study also represents patients who were young or healthy enough to be considered for and actually received AHCT. It is valuable to consider the outcomes of potentially eligible patients that do not pursue transplant. A retrospective study from the International Primary CNS Lymphoma Collaborative Group of 113 patients with isolated brain parenchymal relapse of NHL, suggested that the best outcomes were found in patients aged <60 years and who were treated with high-dose systemic methotrexate (Doolittle et al, 2008). Only ten patients in that cohort underwent AHCT and in this cohort treated primarily with chemotherapy and/or radiotherapy, the median OS from date of CNS relapse was only 1·6 years. Another study from the same study group analysed 92 patients with secondary CNS lymphoma and reported a median OS of 7 months (Bromberg et al, 2013). Only 29% of patients with CNS relapses underwent AHCT although patients were seen at transplant centres. For those who received AHCT, 2-year survival was 54% (vs. 17% in those treated with non-transplant therapy).

Our study is the largest analysis of outcomes after AHCT for patients with NHL and prior CNS lymphoma. We found no significant difference in NRM, progression/relapse, PFS or OS compared to patients with NHL, but without prior CNS lymphoma. A sub-analysis comparing those with CNS disease to a similar matched high risk NHL cohort without CNS involvement also showed no differences in these outcomes. Interestingly, the vast majority of the patients relapsed outside of the CNS, suggesting that the overall therapy for the CNS sanctuary site was adequate. Historically, total body irradiation (TBI) was thought to be a critical element of the conditioning for its CNS penetration, but this cohort (only 23% receiving TBI conditioning) do not substantiate this need. Overall, these data indicate that a history of pre-existing CNS involvement by NHL, by itself, should not exclude patients from AHCT. However, patients within the CNS+ cohort who had active disease at the time of AHCT had much worse outcomes. Achieving disease remission in the CNS compartment prior to transplantation is crucial to optimize the chance of long-term survival.

Our analysis was retrospective, with data collected from over 400 transplant programmes. Insufficient data were available from individual transplant centres regarding the utilisation of post-transplantation adjuvant intrathecal or radiation therapy. Similarly, the outcomes of CNS+ patients who were unable to receive AHCT is beyond the scope of this analysis. Jahnke et al (2006) analysed their institutional experience of patients with systemic lymphoma involving the CNS at time of diagnosis or at relapse. Between 1982 and 2004, 43 patients were identified of which the vast majority were diagnosed with secondary CNS involvement at relapse. The median survival was 5 months and only 26 patients had significant response to treatment. Only three proceeded to autologous transplantation of which two patients were reported with long-term survival (Jahnke et al, 2006). Similarly, although only 29% of patients in the series reported by Bromberg et al (2013) were able to receive AHCT, there was a survival benefit for transplant recipients (estimated 3-year OS of 42%).

This study was also limited to adult patients, recognizing that lymphoblastic lymphoma and Burkitt lymphoma are far more common in the paediatric population. Despite this observation, approximately 25% of the study group included patients with these diagnoses of very aggressive lymphomas, recognizing that their behaviours and their treatments may vary from the indolent and less aggressive lymphomas that make up the bulk of the population. We would hope that these data would contribute to focus efforts in future large, randomized prospective lymphoma trials to collect additional data that would further enhance our understanding of these high-risk patients.

In summary, our data indicate that prior CNS involvement, by itself, should not preclude AHCT for otherwise eligible transplant candidates. Rather, aggressive pretransplant CNS disease management should be the therapeutic goal prior to AHCT as remission within the CNS was most predictive of PFS. These observations may also prove to be beneficial to in the setting of primary CNS lymphoma (Deckert et al, 2011; Ferreri, 2011), recognizing that AHCT is currently being evaluated as part of treatment schedules for early as well as late primary CNS lymphoma. A collaborative analysis of AHCT for this entity has been established between the EBMT and CIBMTR and is forthcoming.

Author contributions

RTM and PNH designed the study and all other authors contributed to the design of the study. ZW and MJZ assembled and analysed the data. All authors participated in the interpretation of the data. RTM. and PNH wrote the first draught of the paper and all other authors contributed to the final version.


The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukaemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukaemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Programme; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defence, or any other agency of the US. Government.